XML 47 R7.htm IDEA: XBRL DOCUMENT v3.20.1
Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Cash flows from operating activities:    
Net loss including noncontrolling interests in subsidiaries $ (11,291) $ (4,398)
Adjustments to reconcile net loss including noncontrolling interests in subsidiaries to net cash provided by (used in) operating activities:    
Change in fair value of investment, net (Note 5) (4,108) (6,908)
Loss on sale of investment (Note 5) 3,316 5,590
Depreciation and amortization 1,064 660
Change in fair value of Series A redeemable convertible preferred stock embedded derivative 3,708 0
Change in fair value of Series A warrants (958) 0
Change in fair value of Series B warrants 1,631 0
Non-cash stock compensation 332 (8)
Change in value of trading securities 6,005 (1,077)
Changes in assets and liabilities:    
Accounts receivable (110) 8,920
Prepaid expenses and other assets (784) (541)
Accounts payable and accrued expenses (908) 2,343
Royalties and contingent legal fees payable (108) (6,539)
Net cash used in operating activities (2,211) (1,958)
Cash flows from investing activities:    
Patent acquisition costs (5,780) 0
Sale of investment at fair value (Note 5) 905 3,294
Purchases of trading securities (29,501) (60,193)
Maturities and sales of trading securities 35,046 3,339
Purchases of property and equipment (163) (6)
Net cash provided by (used in) investing activities 507 (53,566)
Cash flows from financing activities:    
Repurchase of common stock (1,314) 0
Dividend on Series A Redeemable Convertible Preferred Stock (263) 0
Issuance of Series B warrants 4,600 0
Net cash provided by financing activities 3,023 0
Increase (decrease) in cash and cash equivalents and restricted cash 1,319 (55,524)
Cash and cash equivalents and restricted cash, beginning 92,359 128,809
Cash and cash equivalents and restricted cash, ending $ 93,678 $ 73,285